Ampio Pharmaceuticals Coverage Initiated at Citigroup Inc. (AMPE)
Citigroup Inc. initiated coverage on shares of Ampio Pharmaceuticals (NASDAQ:AMPE) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $21.00 price target on the stock. Citigroup Inc.’s price objective points to a potential upside of 198.30% from the company’s current price.
Separately, analysts at Aegis raised their price target on shares of Ampio Pharmaceuticals from $15.00 to $16.00 in a research note on Monday, March 17th. They now have a “buy” rating on the stock.
Shares of Ampio Pharmaceuticals (NASDAQ:AMPE) traded up 8.31% on Thursday, hitting $7.04. 1,601,683 shares of the company’s stock traded hands. Ampio Pharmaceuticals has a 1-year low of $4.31 and a 1-year high of $10.86. The stock’s 50-day moving average is $5.94 and its 200-day moving average is $7.49. The company’s market cap is $296.6 million.
Ampio Pharmaceuticals, Inc (NASDAQ:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.